Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.

Chen, Leon; Aria, Alexander B; Silapunt, Sirunya; Lee, Heng-Huan; Migden, Michael R

Chen, Leon; Aria, Alexander B; Silapunt, Sirunya; Lee, Heng-Huan; Migden, Michael R.

Afiliação

Chen L; Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX 77030, USA.
Aria AB; The University of Texas McGovern Medical School at Houston, Houston, TX 77030, USA.
Silapunt S; Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX 77030, USA.
Lee HH; Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Migden MR; Departments of Dermatology & Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Future Oncol ; 14(6): 515-525, 2018 Mar.

Article em En | MEDLINE | ID: mdl-29119833

ABSTRACT

ABSTRACT

Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be discussed in this review. Additionally, an in-depth analysis of the BOLT trial and data from the 30-month update will be included. This will serve as an update to a previously published article which reported the 12-month update of the BOLT trial.

Assuntos

Antineoplásicos/uso terapêutico; Compostos de Bifenilo/uso terapêutico; Carcinoma Basocelular/tratamento farmacológico; Carcinoma Basocelular/patologia; Piridinas/uso terapêutico; Neoplasias Cutâneas/tratamento farmacológico; Neoplasias Cutâneas/patologia; Antineoplásicos/administração & dosagem; Antineoplásicos/efeitos adversos; Compostos de Bifenilo/administração & dosagem; Compostos de Bifenilo/efeitos adversos; Seguimentos; Humanos; Terapia de Alvo Molecular; Piridinas/administração & dosagem; Piridinas/efeitos adversos; Resultado do Tratamento

Palavras-chave

BOLT; HPI; basal cell carcinoma; hedgehog pathway inhibitor; laBCC; locally advanced basal cell carcinoma; mBCC; metastatic basal cell carcinoma; sonidegib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Neoplasias Cutâneas / Compostos de Bifenilo / Carcinoma Basocelular / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google